United Asset Strategies Inc. Sells 10,128 Shares of Thermo Fisher Scientific Inc. $TMO

United Asset Strategies Inc. lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 27.9% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,211 shares of the medical research company’s stock after selling 10,128 shares during the period. United Asset Strategies Inc.’s holdings in Thermo Fisher Scientific were worth $10,627,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Revolve Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares during the last quarter. Lafayette Investments Inc. grew its stake in shares of Thermo Fisher Scientific by 2.4% during the 2nd quarter. Lafayette Investments Inc. now owns 927 shares of the medical research company’s stock valued at $376,000 after purchasing an additional 22 shares during the period. Rossmore Private Capital increased its holdings in Thermo Fisher Scientific by 0.5% during the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company’s stock valued at $2,315,000 after buying an additional 24 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH increased its stake in shares of Thermo Fisher Scientific by 3.1% in the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 803 shares of the medical research company’s stock worth $326,000 after purchasing an additional 24 shares in the last quarter. Finally, Somerville Kurt F raised its stake in shares of Thermo Fisher Scientific by 1.6% in the second quarter. Somerville Kurt F now owns 1,605 shares of the medical research company’s stock worth $651,000 after buying an additional 25 shares during the period. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Up 1.7%

Shares of NYSE:TMO opened at $586.37 on Wednesday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The business has a 50 day moving average of $522.26 and a two-hundred day moving average of $465.01. The company has a market capitalization of $220.30 billion, a PE ratio of 33.87, a PEG ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same quarter in the previous year, the firm earned $5.28 EPS. The firm’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has authorized a stock repurchase program on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 2.4% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TMO. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 24th. Argus raised their price target on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. HSBC restated a “hold” rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Finally, JPMorgan Chase & Co. increased their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Nineteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $601.65.

Insider Activity at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $574.15, for a total value of $229,660.00. Following the completion of the sale, the executive vice president directly owned 21,152 shares in the company, valued at $12,144,420.80. This represents a 1.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 46,645 shares of company stock worth $25,825,699. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.